Newsfeeds - Spark Newswire

3 minute read

Why Virios Therapeutics Is Trading Lower By 75%, Here Are 44 Stocks Moving In Tuesday’s Mid-Day Session

Today, 4:49 PM

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 51% to $0.4957. Crown ElectroKinetics, last month, posted a Q4 net loss of $4.5 million.

ADXN

1 minute read

HC Wainwright & Co. Maintains Buy on Spectrum Pharmaceuticals, Lowers Price Target to $9

By Benzinga Newsdesk

Today, 4:49 PM

HC Wainwright & Co. analyst Edward White maintains Spectrum Pharmaceuticals (NASDAQ:SPPI) with a Buy and lowers the price target from $12 to $9.

SPPI

1 minute read

The U.S. FDA Staff Raised Concerns Over The Safety Of Spectrum Pharmaceutical’s; Experimental Cancer Drug And Questioned The Benefits It Provided Over Existing Therapies, The Staff’s Concerns Over Poziotinib Were Raised In The Regulator’s Briefing Docu…

By Benzinga Newsdesk

Today, 4:49 PM

- Reuters

SPPI

4 minute read

Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 4:49 PM

Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.

AKTX

1 minute read

Analyst Ratings

HC Wainwright & Co. Maintains Buy Rating for Spectrum Pharmaceuticals: Here’s What You Need To Know

By Benzinga Insights

Today, 4:49 PM

HC Wainwright & Co. has decided to maintain its Buy rating of Spectrum Pharmaceuticals (NASDAQ:SPPI) and raise its price target from $10.00 to $12.00. Shares of Spectrum Pharmaceuticals are trading up 5.79% over the last 24 hours, at $1.37 per share.

SPPI

3 minute read

Why Clovis Oncology Is Trading Higher By 14%; Here Are 28 Stocks Moving Premarket

By Lisa Levin

Today, 4:49 PM

Gainers Aditxt, Inc. (NASDAQ: ADTX) rose 46.1% to $0.2801 in pre-market trading after jumping 37% on Friday.

ADTX

3 minute read

Important Biotech Catalysts For September 9, 2022 – End Of The Day Summary

By Ragothaman Srinivasan

Today, 4:49 PM

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to…

ADAP

1 minute read

Spectrum Gets FDA Nod For Febrile Neutropenia Candidate, Sees Commercial Launch In Q4 2022

By Ragothaman Srinivasan

Today, 4:49 PM

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ: SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia.

SPPI

1 minute read

News

Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection

By Michael Horton

Today, 4:49 PM

First novel Long-Acting GCSF (LA-GCSF) product approved in over 20 years ROLVEDON™ developed using proprietary LAPSCOVERY™ technology with a differentiated molecular structure and proven safety and

SPPI

1 minute read

News

Spectrum Pharmaceuticals’ Website Says ROLVEDON Has Been Approved

By Michael Horton

Today, 4:49 PM

https://www.sppirx.com/

SPPI